EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 27 / No 5 (Mai 2011) Med Sci (Paris), 27 5 (2011) 493-500 References
Free Access
Issue
Med Sci (Paris)
Volume 27, Number 5, Mai 2011
Page(s) 493 - 500
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2011275014
Published online 25 May 2011
  1. Wienen W, Stassen JM, Priepke H, et al. In vitro profile and ex vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007 ; 98 : 155-162. [PubMed] [Google Scholar]
  2. DuBuske LM. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf 2005 ; 28 : 789-801. [CrossRef] [PubMed] [Google Scholar]
  3. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008 ; 47 : 285-295. [CrossRef] [PubMed] [Google Scholar]
  4. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006 ; 46 : 549-558. [CrossRef] [PubMed] [Google Scholar]
  5. Carreiro J, Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 2008 ; 17 : 1937-1945. [CrossRef] [PubMed] [Google Scholar]
  6. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban: an oral, direct factor Xa inhibitor. Thromb Haemost 2011 ; 103 : 815-825. [CrossRef] [Google Scholar]
  7. Liesenfeld KH, Schäfer HG, Trocóniz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006 ; 62 : 527-537. [CrossRef] [PubMed] [Google Scholar]
  8. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007 ; 5 : 2178-2185. [CrossRef] [PubMed] [Google Scholar]
  9. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 ; 370 : 949-956. [CrossRef] [PubMed] [Google Scholar]
  10. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009 ; 24 : 1-9. [Google Scholar]
  11. Trocóniz IF, Tillmann C, Liesenfeld KH, et al. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 2007 ; 47 : 371-382. [CrossRef] [PubMed] [Google Scholar]
  12. Friedman RJ, Dahl OE, Rosencher N, et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010 ; 126 : 175-182. [CrossRef] [PubMed] [Google Scholar]
  13. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008 ; 358 : 2765-2775. [CrossRef] [PubMed] [Google Scholar]
  14. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008 ; 372 : 31-39. [CrossRef] [PubMed] [Google Scholar]
  15. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008 ; 358 : 2776-2786. [CrossRef] [PubMed] [Google Scholar]
  16. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009 ; 373 : 1673-1680. [CrossRef] [PubMed] [Google Scholar]
  17. Van Thiel D, Kalodiki E, Wahi R, et al. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost 2009 ; 15 : 389-394. [CrossRef] [PubMed] [Google Scholar]
  18. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010 ; 375 : 807-815. [CrossRef] [PubMed] [Google Scholar]
  19. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009 ; 157 : 805-10-810 e1-2. [Google Scholar]
  20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 ; 361 : 1139-1151. [CrossRef] [PubMed] [Google Scholar]
  21. Rocket AF. Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010 ; 159 : 340-347. [CrossRef] [PubMed] [Google Scholar]
  22. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010 ; 159 : 331-339. [CrossRef] [PubMed] [Google Scholar]
  23. Eikelboom JW, O’Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010 ; 159 : 348-353. [CrossRef] [PubMed] [Google Scholar]
  24. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009 ; 361 : 2342-2352. [Google Scholar]
  25. Buller HR. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The Einstein-extension study. ASH Annual Meeting Abstracts 2009 ; 114 : LBA-2. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.